Hoth Therapeutics, Inc.
HOTHNASDAQHealthcare
$1.36
$-0.15(-9.93%)
Market Cap$18032277
P/E Ratio—
52W High$2.45
52W Low$0.4894
Hoth Therapeutics, Inc. (HOTH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HOTH · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.17
Est. -$0.14 · -23.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS
HOTH reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | -$0.14 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.14 | -$0.17 | -23.4% | — | — | — |
| ▼ Q1 FY2026 | Mar 27, 2026 | -$0.10 | -$0.16 | -55.2% | — | — | — |
| — Q4 FY2025 | Nov 12, 2025 | -$0.30 | -$0.30 | +0.0% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.27 | -$0.17 | +37.0% | — | — | — |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.34 | -$0.27 | +20.6% | — | — | — |
| ▲ Q1 FY2025 | Mar 28, 2025 | -$0.39 | -$0.32 | +17.9% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.30 | -$0.31 | -3.3% | — | — | — |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$0.14
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$0.17
EPS Est.
-$0.14
EPS Surpr.
-23.4%
Revenue
—
Q1 FY2026
Mar 27, 2026Miss
EPS Actual
-$0.16
EPS Est.
-$0.10
EPS Surpr.
-55.2%
Revenue
—
Q4 FY2025
Nov 12, 2025
EPS Actual
-$0.30
EPS Est.
-$0.30
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.17
EPS Est.
-$0.27
EPS Surpr.
+37.0%
Revenue
—
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.27
EPS Est.
-$0.34
EPS Surpr.
+20.6%
Revenue
—
Q1 FY2025
Mar 28, 2025Beat
EPS Actual
-$0.32
EPS Est.
-$0.39
EPS Surpr.
+17.9%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.31
EPS Est.
-$0.30
EPS Surpr.
-3.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Q3 FY2028 | $-0.31 | $-0.31 | $-0.31 | 1 |
| Q2 FY2028 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q1 FY2028 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q4 FY2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q3 FY2027 | $-0.18 | $-0.18 | $-0.18 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -23.4% | $0.67 | $0.63 | -4.94% |
| ▼ Q1 FY2026 | Mar 27, 2026 | -55.2% | $0.84 | $0.81 | -3.97% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +0.0% | $1.28 | $1.28 | +0.00% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +37.0% | $1.16 | $1.27 | +9.48% |
| ▲ Q2 FY2025 | May 12, 2025 | +20.6% | $0.95 | $0.93 | -2.47% |
| ▲ Q1 FY2025 | Mar 28, 2025 | +17.9% | $1.00 | $1.03 | +3.00% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -3.3% | $0.89 | $0.90 | +1.01% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +38.5% | $0.63 | $0.61 | -2.55% |
Q2 FY2026-4.94%
Report Date
May 15, 2026
EPS Beat/Miss
-23.4%
Price Before
$0.67
Price After
$0.63
Q1 FY2026-3.97%
Report Date
Mar 27, 2026
EPS Beat/Miss
-55.2%
Price Before
$0.84
Price After
$0.81
Q4 FY2025+0.00%
Report Date
Nov 12, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.28
Price After
$1.28
Q3 FY2025+9.48%
Report Date
Aug 12, 2025
EPS Beat/Miss
+37.0%
Price Before
$1.16
Price After
$1.27
Q2 FY2025-2.47%
Report Date
May 12, 2025
EPS Beat/Miss
+20.6%
Price Before
$0.95
Price After
$0.93
Q1 FY2025+3.00%
Report Date
Mar 28, 2025
EPS Beat/Miss
+17.9%
Price Before
$1.00
Price After
$1.03
Q4 FY2024+1.01%
Report Date
Nov 12, 2024
EPS Beat/Miss
-3.3%
Price Before
$0.89
Price After
$0.90
Q3 FY2024-2.55%
Report Date
Aug 9, 2024
EPS Beat/Miss
+38.5%
Price Before
$0.63
Price After
$0.61
Avg Beat Reaction+1.49%
Avg Miss Reaction-2.63%
Beat Rate5 / 8 quarters
Largest Move+9.48% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HOTH ends December
Hoth Therapeutics, Inc. (HOTH) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.17 — missing the analyst consensus of $-0.14 by -23.4%. The next HOTH earnings date is expected around September 1, 2026.
Each quarter, investors track HOTH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HOTH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HOTH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HOTH earnings · 5 questionsHoth Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. HOTH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HOTH historically reports after market close (AMC).
HOTH earnings datewhen is HOTH earningsHOTH next earnings datewhen does HOTH report earningsHOTH earnings calendar
▸ Source: FMP · Hoth Therapeutics, Inc. SEC filings · US GAAP · Hoth Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026